Expression of EGFR family and p 53 in a patient with Synchronous Primary Endometrial Adenocarcinoma and Clear Cell Renal Carcinoma : a Case Report

Braz J Oncol. 2019; 00(Supl): 0-00 1 Expression of EGFR family and p53 in a patient with Synchronous Primary Endometrial Adenocarcinoma and Clear Cell Renal Carcinoma: a Case Report Expressão da família EGFR e p53 em paciente com Adenocarcinoma Endometrial e Carcinoma Renal de Células Claras primários e sincrônicos: Relato de Caso Priscila Fernanda da Silva Martins1, Izabella Cristina Alves Souza1, Enio Ferreira2, Emerson Soares Veloso2, Tatiany L Silveira2, Adam Underwood3, Fabiano Conde Araujo4, Helen Lima Del-Puerto2


INTRODUCTION
When patients have more than one tumor in the same or different organs/tissues, it is expected a hereditary predisposition to multiple tumors.Overall, based on an analysis of several studies, the incidence of multiple primary tumors is reported to be around 0.73-5.2%. (1) In patients diagnosed with two malignancies simultaneously, a major challenge is to find an anticancer therapy strategy to treat both cancer types without increasing toxicity or pharmacological interactions, and without negative impact on overall outcome. (2,3)Caucasian ancestry, cancer diagnostic at younger age, lower grade with indolent clinical behavior with longer survival, and cancer family history are reported as risk factors for multiple primary tumors. (1)man epidermal growth factor receptor (HER) family members have been shown to be involved in oncogenesis in a number of human cancers. (4)In endometrial cancer, the expression of EGFR has been noted in 43-67% of cases and is associated with a decrease in disease-free and overall Survival. (4)In renal cell carcinoma (RCC) EGFR expression is higher in primary RCC specimens compared with benign renal parenchyma, indicating its possible role in tumor development and progression. (5)EGFR expression is often heterogeneous within clear cell RCC, where it has been described as negative, weakly positive, and strongly positive staining. (6)rmal endometrium had a mild HER-2 protein expression regardless of the phase of the menstrual cycle. (7)In endometrial cancer the HER-2 expression directly correlates with disease stage, grade, and non-endometrioid tumor subtype, suggesting that HER-2 has potential use as a biomarker for predicting disease stage, tumor aggressiveness and prognosis. (7)rmal endometrial glands and stroma show weak to moderate expression of HER-4.HER-4 and its ligands have also been noted to be more highly expressed during the secretory phase versus the proliferative phase of the menstrual cycle, suggesting a possible involvement in maturation and anti-proliferative effects in the endometrium.HER-4 is expressed at a lower level in endometrial cancer and is overexpressed in approximately 15% of cases. (8)Furthermore, Thomasson et al. (9) evaluated HER-4 gene and protein expression in normal kidney parenchyma compared to renal carcinomas from 31 patients and observed that HER-4 mRNA expression in RCC tumor tissue was significantly reduced compared with normal matched kidney cortex. (9)erefore, the aim of the present study it was to correlate synchronous immunohistochemistry expression of the EGFR family and p53 in a synchronous endometrial and renal primary tumor, and also correlate with tumors grade and histological characteristics.

Case description
The patient was a 69 year-old, non-obese, post-menopausal woman, with no vaginal bleeding, abdominal pain or urinary symptoms.She was diagnosed with synchronous endometrial adenocarcinoma and clear cells renal cell carcinoma (RCC), and anatomopathological characteristics of tumors are describe on Table 1.Of note in her medical history, she regularly took medications with paracetamol for back pain.She has a sister with a history of breast cancer at age 54, diagnosed as invasive ductal carcinoma grade II (cancer-free for sixteen years), and a brother who died at age 83 with grade 2 follicular lymphoma.The patient in the present study has been cancer-free since surgery 4 years ago; no other treatment was advised besides regular follow up imaging.Protein expression analysis was performed in both tumors of this patient, and fixed paraffin-embedded tissue sections were processed for immunohistochemistry (IHC) staining using the ABC (avidin-biotin complex) method, following the protocol shown in Table 2.As a positive IHC control for EGFR, HER-2, HER-3 and HER-4, canine mammary specimens were used (Figure 1), in a well-established routine protocol in collaboration with the Comparative Pathology Laboratory at UFMG (Laboratório de Patologia Comparada -LPC) (Figure 1).
Results from endometrial adenocarcinoma IHC staining confirmed a well-differentiated tumor (FIGO grade 1), with an epithelial growth pattern, areas of budding and branching of glands forming papillary structures, endometrioid type, nuclear grade 2, and with moderate mitotic index.Results from the renal cell carcinoma confirmed a clear cell type, solid tu-mor, Fuhrman nuclear grade 2, with areas of necrosis and hemorrhage.
In the present investigation HER-2, HER-4 and EGFR expression was present in both primary tumors.HER-2 was weakly expressed in both endometrioid and renal cell carcinomas.However, HER-4 was localized in nuclei of the renal cell carcinoma (Figure 3), with 50% positive staining of the tubules and glomerulus (Figure 3), although the endometrioid adenocarcinoma revealed an intense membrane staining (Figure 3).EGFR expression in clear cells RCC was positive, with moderate membranous staining in 90% of the cells (Figure 2), and in the endometrioid adenocarcinoma EGFR stained weakly in epithelial cells (Figure 2).
No HER-3 expression was evident, and p53 was detected only in the papillary areas of the endometrioid adenocarcinoma (Figures 2 and 3).

DISCUSSION
HER-2 expression is associated with high grade endometrioid adenocarcinoma, and HER-2 overexpression is linked to poor prognostics because of a more aggressive tumor behavior. (10,11)In the present investigation HER-2 was weakly expressed in endometrioid adenocarcinoma, and this IHC result is in accordance to the patient good prognosis, since she has been cancer-free for 4 years, and with patient's tumor histological grade.With regard to the RCC, our results showed that HER-2 expression is rare in clear cells renal cell carcinoma, in accordance to Wang et  al. (2012) that showed a reduced HER-2 expression during the development, oncogenesis and progression of RCC. (12)cording to Thomasson et al. ( 2004), (9) HER-4 is a tumor suppressor in most RCCs, and it is related with a good prognosis.In addition, Srinivasan et al. (1999) (8) showed HER-4 overexpression in endometrioid adenocarcinoma compared to normal endometrium.In clear cell RCC evaluated in the present study, HER-4 was localized in nuclei of the clear cells RCC, and endometrioid adenocarcinoma revealed an intense HER-4 membrane staining (Figure 3).
EGFR receptor overexpression is related to initiation and tumor progression in RCC, (13) and in the present patient it was observed 90% of clear cells RCC with EGFR moderate staining, indicating its relation to tumor initiation.6)(17) The p53 mutation in endometrial carcinoma is related to tumor survival and metastasis risk, (18) however, in the endometrioid adenocarcinoma it was observed p53 immunostaining only in papillary area of the tumor.At the present investigation in clear cells RCC p53 expression was negative (Figure 2), but nevertheless p53 expression is considered rare in clear cells RCC, in relation to other types of renal carcinomas. (19) conclusion, HER-2, HER-4 and EGFR proteins were found synchronously expressed in both primary tumors, and their expression in the present study is consistent with their histological grade and patient cancer-free status, and it is also in accordance to literature on the HER-2, HER-4 and EGFR proteins expression behavior in both tumors.Future studies to investigate genetic instability in EGFR family DNA sequence may clarify if the synchronous proteins expression in both primary tumors it is an important trigger for cancer in those cases.

Figure 2 .
Figure 2. Immunohistochemistry (IHC) for EGFR, HER-2 and p53 in endometrial carcinoma and clear cell renal carcinoma.A: H&E -endometrial carcinoma glandular area.B: EGFR IHC -Intense staining of EGFR in stromal area, and weak staining in glandular area of endometrial carcinoma.C: HER-2 IHC -Weak staining of HER-2 in endometrial carcinoma glandular area.D: p53 IHC -negative staining of p53 in endometrial carcinoma glandular area.E: H&E -endometrial carcinoma papillary area.F: EGFR IHC -Moderate staining of EGFR in stromal area, and negative staining in epithelial cells of endometrial carcinoma papillary area.G: HER-2 IHC -Negative staining of HER-2 in endometrial carcinoma papillary area.H: p53 IHC -Intense staining of p53 in endometrial carcinoma papillary area.I: H&E -Clear cells renal carcinoma.J: EGFR IHC -moderate staining of EGFR in CCR.L: HER-2 IHC -Weak staining of HER-2 in CCR.M: p53 IHC -negative staining of p53 in CCR.